Pfizer Manufacturing Deutschland GmbH – FDA 483, Feb 3, 2020
An FDA inspection of Pfizer Manufacturing Deutschland GmbH in Freiburg im Breisgau, Germany, revealed significant deficiencies in their quality control unit, process controls, and discrepancy investigations. Observations included a lack of quality unit oversight for critical manufacturing documentation and calibration records, absence of written procedures for assessing process alarms, and failure to thoroughly review unexplained discrepancies such as stability chamber excursions and deviation reports. These issues indicate a need for improved quality system implementation to ensure drug product quality and purity.
ID · 9c532bb6-5a61-4a3d-8875-72387ba64b86
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.